866-997-4948(US-Canada Toll Free)

Amyloidosis - Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Jan 2018

Category :

Pharmaceutical

No. of Pages : 182 Pages

Amyloidosis - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H1 2018, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.

Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyloidosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 3, 6, 8, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 2 molecules, respectively.

Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Amyloidosis - Overview 6
Amyloidosis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 15
Amyloidosis - Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Amyloidosis - Companies Involved in Therapeutics Development 24
Alnylam Pharmaceuticals Inc 24
Amgen Inc 24
Arcturus Therapeutics Ltd 25
Bsim2 25
Celgene Corp 26
Chugai Pharmaceutical Co Ltd 26
GlaxoSmithKline Plc 27
Ionis Pharmaceuticals Inc 27
Johnson & Johnson 28
Millennium Pharmaceuticals Inc 28
Neurimmune Holding AG 29
Novartis AG 29
Oncopeptides AB 30
Pfizer Inc 30
Prothena Corp Plc 31
R Pharm 31
Regeneron Pharmaceuticals Inc 32
Spectrum Pharmaceuticals Inc 32
Amyloidosis - Drug Profiles 33
AG-10 - Drug Profile 33
ALN-TTRsc02 - Drug Profile 35
birtamimab - Drug Profile 37
CAEL-101 - Drug Profile 44
canakinumab - Drug Profile 46
carfilzomib - Drug Profile 54
Cellular Immunotherapy to Target CS1 for Metabolic Disorders and Oncology - Drug Profile 68
CLR-01 - Drug Profile 69
CRX-1008 - Drug Profile 71
daratumumab - Drug Profile 73
dezamizumab + GSK-2315698 - Drug Profile 91
doxycycline hyclate - Drug Profile 92
EDE-1307 - Drug Profile 93
GSK-2315698 - Drug Profile 94
GSK-3039294 - Drug Profile 95
inotersen sodium - Drug Profile 96
ixazomib citrate - Drug Profile 102
LUNAR-TTR - Drug Profile 113
melphalan - Drug Profile 114
melphalan flufenamide - Drug Profile 118
Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile 121
NI-301 - Drug Profile 122
NPT-189 - Drug Profile 123
Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile 124
patisiran - Drug Profile 125
pomalidomide - Drug Profile 135
PRX-004 - Drug Profile 142
RPH-104 - Drug Profile 143
Small Molecule to Inhibit Amyloid Beta Peptide for Alzheimer's Disease and Amyloidosis - Drug Profile 144
Small Molecules to Activate ATF6 for Amyloidosis - Drug Profile 145
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile 146
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile 147
tafamidis meglumine - Drug Profile 148
tocilizumab - Drug Profile 152
VERU-111 - Drug Profile 163
VERU-112 - Drug Profile 164
Amyloidosis - Dormant Projects 165
Amyloidosis - Discontinued Products 166
Amyloidosis - Product Development Milestones 167
Featured News & Press Releases 167
Appendix 178
Methodology 178
Coverage 178
Secondary Research 178
Primary Research 178
Expert Panel Validation 178
Contact Us 178
Disclaimer 179

List of Tables
Number of Products under Development for Amyloidosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
Amyloidosis - Pipeline by Amgen Inc, H1 2018
Amyloidosis - Pipeline by Arcturus Therapeutics Ltd, H1 2018
Amyloidosis - Pipeline by Bsim2, H1 2018
Amyloidosis - Pipeline by Celgene Corp, H1 2018
Amyloidosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Amyloidosis - Pipeline by GlaxoSmithKline Plc, H1 2018
Amyloidosis - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Amyloidosis - Pipeline by Johnson & Johnson, H1 2018
Amyloidosis - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Amyloidosis - Pipeline by Neurimmune Holding AG, H1 2018
Amyloidosis - Pipeline by Novartis AG, H1 2018
Amyloidosis - Pipeline by Oncopeptides AB, H1 2018
Amyloidosis - Pipeline by Pfizer Inc, H1 2018
Amyloidosis - Pipeline by Prothena Corp Plc, H1 2018
Amyloidosis - Pipeline by R Pharm, H1 2018
Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2018
Amyloidosis - Dormant Projects, H1 2018
Amyloidosis - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Amyloidosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *